solution by MARKET
Pharmaceutical Production Lines & Turnkey Factory Solutions for Egypt
From IV solution filling lines and injectable systems to OSD plants, biologics equipment, and cleanroom engineering — GMP-compliant manufacturing infrastructure built for the MENA region’s largest pharmaceutical manufacturing base and Africa’s gateway for pharma exports.
A Clear View of the Local Market Landscape
Egypt’s pharmaceutical market reached USD 6.5 billion in 2024 and is projected to reach USD 13.8 billion by 2033, at a CAGR of 8.74%. Egypt has the largest drug manufacturing base in the Middle East and North Africa, accounting for nearly 30% of the regional market, with between 170 and 200 pharmaceutical companies and a self-sufficiency rate of 91.3% in medicine production by volume. Yet Egypt still imports about $3.5 billion in pharmaceutical products annually, including finished medicines and active ingredients, and imports nearly 80% of its raw materials for drug production — making pharmaceutical localization, capacity expansion, and export growth national strategic priorities under Egypt’s Vision 2030.
Demand Trends Within the Country
-
Pharmaceutical Manufacturing Localization
President Abdel Fattah El Sisi has tasked the government with developing an executive plan aimed at expanding the localization of the pharmaceutical industry, with the government focusing on localising specialised pharmaceutical industries, primarily oncology and immunodeficiency drugs, radioactive dyes, and infant formula. -
Injectable, IV Solution & Biologics Production
Egypt currently imports about 95% of its oncology drugs, and the push to build domestic capacity for sterile injectables, IV fluids, biologics, biosimilars, and vaccines is a top national priority. -
OSD & Generic Drug Manufacturing
Around 70% of production is generic medicine, and the market is experiencing a surge in demand for generic drugs due to their affordability and accessibility — making tablet and capsule production line expansion a core investment focus. -
Export-Oriented Capacity Expansion
In 2024, Egypt exported pharmaceuticals to over 147 countries, and Fitch forecasted Egypt’s pharma exports would grow almost 40% between 2025 and 2029, driving demand for new GMP-compliant production facilities positioned for African, Middle Eastern, and global export markets.
Local Experience, Reliable Execution
-
Proven MENA & Africa delivery track record — 2,500+ production lines deployed in 60+ countries, with extensive project experience across the Middle East and North African pharmaceutical markets.
-
EDA & international GMP alignment — All systems pre-engineered to meet WHO GMP, EU GMP, US FDA cGMP, and PIC/S GMP standards, fully aligned with EDA inspection requirements. EDA’s inspection department inspects factories to ensure compliance with the GMP of the WHO and local regulations.
-
Full turnkey EPC capability — From consulting and process design through equipment manufacturing, cleanroom construction, utility installation, IQ/OQ/PQ validation, technology transfer, and operator training — one partner, one contract.
-
Customized for Egypt’s strategic priorities — Solutions tailored for localization of oncology drugs, biologics, IV solutions, and generics — configured for both domestic supply and African/MENA export, including pharma park and Suez Canal Economic Zone facility requirements.
Selected Products for This Market
-
Fully Automatic Production Line for Insulin Pen Needle
Machine Layout Technological Process Machine function Specifications ● Utilization rate: ≥ 95%; Pass rate: ≥ 98% ● Capacity = 24000 pcs/H ● Specifications for: 29G 30G 31G 32G 33G 34G ● Power: 30 kW ● Air pressure: 0.6~0.8 Mpa, 1.5m3/Min ● Size: L×W×H=9500×5500×2000 mm -
Automatic Blister Packing & Cartoning Machine
The line typically consists of a number of different machines, including a blister machine, a cartoner, and a labeller. The blister machine is used to form the blister packs, the cartoner is used to package the blister packs into cartons, and the labeller is used to apply labels to the cartons. -
Storage Tank
Product Detail Introduction This equipment can be used in medicine, food, chemical industry, liquid material storage. Has a beautiful appearance, easy operation, the tank is equipped with automatic rotating cleaning head, to ensure thorough cleaning, materials used SUS304 or SUS316L, with mirror polished or matte surface treatment, meet the GMP standard. Product Video Parameters Model…
Meeting Local Standards with Reliable Delivery
Compliance & Certification
Logistics & Delivery
Success Snapshot
-
Pharmaceutical Manufacturer
Delivered an integrated injectable production facility including vial filling line with lyophilization, WFI system, Grade A/B cleanroom, and automated packaging. The facility passed EDA GMP inspection on first audit and achieved annual fill-finish capacity of 30 million vials, enabling the client to supply oncology and antibiotic products domestically while exporting to 8 African countries.
-
Generic Pharma Company
Supplied a complete OSD turnkey plant including tablet and capsule lines, purified water system, cleanroom, and blister packaging. The project was completed in 15 months and achieved EDA operation licensing, enabling production of 20 generic products for the domestic market and MENA export — with annual capacity of 600 million tablets and 150 million capsules.
Trusted by Local Customers
-
“IVEN delivered our entire injectable facility as a single turnkey project — filling line, lyophilizer, cleanroom, water system, and packaging. Their understanding of EDA requirements and WHO GMP standards accelerated our approval significantly. We’re now exporting to multiple African markets.”
Dr. H
VP of Manufacturing
-
“Their OSD factory solution gave us everything under one contract — from granulation to packaging. The technology transfer was thorough, and our Egyptian operators were production-ready within weeks of commissioning.”
Mr. S
Plant Director
FAQ
Related Market Solutions
Pharmaceutical Production Lines & Turnkey Factory Solutions for Russia
From IV solution filling lines and OSD plants to injectable systems, biologics equipment, and cleanroom engineering — GMP-compliant manufacturing infrastructure built to support Russia’s Pharma 2030 import substitution and full-cycle localization strategy.
